G-CSF是有希望增加癌症化疗安全度与有效性的新药,已于最近应市。G-CSF是人粒细胞克隆刺激因子(商品名为Neu-papen),能激发生成抗感染的白细胞,该药适用于减少骨髓抑制。骨髓抑制症状常发生在化疗患者身上,因为化疗会对细胞产生不良反应。G-CSF是存在于血生成素生长因子中的一种物质,该物质在骨髓生成和释放血细胞的过程中起调节作用。G-CSF可特异性地激发粒细胞(主要为噬中性粒细胞),而其它生长因子则作用于其它类型的细胞,如红细胞生成素,刺激红细胞的生成。G-CSF是由大肠杆菌运用生物工程技术制备的。由美国生化技术公司Amgen和Roche联合开发,并由位于英国的这两公司生产应市。该药在注册时 G-CSF is a promising new drug that has the potential to increase the safety and efficacy of cancer chemotherapy and has recently become available. G-CSF, a human granulocyte colony stimulating factor (also known as Neu-papen), stimulates the production of anti-infective leukocytes, which is indicated for myelosuppression. Myelosuppression symptoms often occur in patients with chemotherapy because chemotherapy can adversely affect the cells. G-CSF is a substance present in the blood growth factor, which regulates bone formation and release of blood cells. G-CSF can specifically stimulate granulocytes (mainly neutrophils), while other growth factors act on other types of cells, such as erythropoietin, to stimulate the production of red blood cells. G-CSF is produced by E. coli using bioengineering techniques. Developed jointly by Amgen and Roche, a biotech company in the United States, these two companies, based in the UK, should be made available. The drug is registered